利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

79 条记录 (耗时 0.028 秒)

    Blood coagulation assays
    1.
    发明授权
    Blood coagulation assays 有权
    血液凝固测定

    公开(公告)号：US08304205B2

    公开(公告)日：2012-11-06

    申请号：US12569714

    申请日：2009-09-29

    申请人： Andreas Kappel ,  Andrea Lichte ,  Norbert Zander ,  Stefan Teigelkamp ,  Sabine Teigelkamp, legal representative ,  Carsten Schelp

    发明人： Andreas Kappel ,  Andrea Lichte ,  Norbert Zander ,  Stefan Teigelkamp ,  Carsten Schelp

    IPC分类号： C12Q1/56 ,  G01N33/53

    CPC分类号： C12Q1/56 ,  G01N2333/974

    摘要： The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.

    摘要翻译： 本发明涉及确定体液如全血或血浆中凝血级联蛋白水解凝血因子的活性的方法。 在反应混合物中提供组合。 该组合包括样品和用于激活凝血级联的蛋白水解凝血因子或用于激活凝血级联的活化剂。 评估活化对包含可切割部分的试剂体系的影响。 可切割部分是化学发光剂或敏化剂或二者结合。 化学发光剂和敏化剂的作用在于，当紧邻时，敏化剂的通电导致化学发光剂的通电。 活化的作用与血液凝固级联的蛋白水解凝血因子的活性有关，其中效应是切割部分的切割程度。

    Blood Coagulation Assays
    2.
    发明申请
    Blood Coagulation Assays 有权
    血液凝固测定

    公开(公告)号：US20100086953A1

    公开(公告)日：2010-04-08

    申请号：US12569714

    申请日：2009-09-29

    申请人： Andreas Kappel ,  Andrea Lichte ,  Norbert Zander ,  Stefan Teigelkamp ,  Sabine Teigelkamp

    发明人： Andreas Kappel ,  Andrea Lichte ,  Norbert Zander ,  Stefan Teigelkamp ,  Sabine Teigelkamp

    IPC分类号： C12Q1/56

    CPC分类号： C12Q1/56 ,  G01N2333/974

    摘要： The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.

    摘要翻译： 本发明涉及确定体液如全血或血浆中凝血级联蛋白水解凝血因子的活性的方法。 在反应混合物中提供组合。 该组合包括样品和用于激活凝血级联的蛋白水解凝血因子或用于激活凝血级联的活化剂。 评估活化对包含可切割部分的试剂体系的影响。 可切割部分是化学发光剂或敏化剂或二者结合。 化学发光剂和敏化剂的作用在于，当紧邻时，敏化剂的通电导致化学发光剂的通电。 活化的作用与凝血级联的蛋白水解凝血因子的活性有关，其中效应是切割部分的切割程度。

    IN VITRO METHOD FOR DIAGNOSING TUMOR DISEASES
    5.
    发明申请
    IN VITRO METHOD FOR DIAGNOSING TUMOR DISEASES 审中-公开
    用于诊断肿瘤疾病的体外方法

    公开(公告)号：US20100247438A1

    公开(公告)日：2010-09-30

    申请号：US12731499

    申请日：2010-03-25

    申请人： Arne Hengerer ,  Andreas Kappel ,  Luis Lasalvia ,  Andrea Lichte ,  Thomas Mertelmeier ,  Sven Meyburg ,  Christoph Petry ,  Marcus Pfister ,  Martin Requardt

    发明人： Arne Hengerer ,  Andreas Kappel ,  Luis Lasalvia ,  Andrea Lichte ,  Thomas Mertelmeier ,  Sven Meyburg ,  Christoph Petry ,  Marcus Pfister ,  Martin Requardt

    IPC分类号： A61K49/00 ,  G01N33/53 ,  G01N33/573 ,  G01N33/48 ,  A61B1/00

    CPC分类号： G01N33/57488 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57473 ,  G01N2333/585 ,  G01N2333/70503 ,  G01N2333/96486

    摘要： An in vitro method is for diagnosing a tumor disease in a patient. In at least one embodiment, the method includes: (i) determining an IVD marker or an IVD marker panel in at least one biological sample of a patient, wherein the IVD marker has a high sensitivity to the tumor disease, (ii) determining the proportion of patients tested positive due to an adapted reference range of the IVD marker/IVD marker panel, wherein the reference range was adapted such that the number of individuals with false negative tests, the number of individuals with false positive tests and the number of individuals ultimately needing to be subjected to imaging diagnostics to clarify false negative and false positive results are balanced in respect of one another such that tumor screening can be carried out, possibly: (iii) deciding to carry out an imaging method specific to the respective tumor disease for clarifying possible false negative and/or false positive IVD results, or (iv) repeating stages (i) and (ii) after a defined time interval, or (v) carrying out an imaging method for imaging the tumor.

    摘要翻译： 体外方法是用于诊断患者的肿瘤疾病。 在至少一个实施方案中，该方法包括：（i）确定患者的至少一个生物样品中的IVD标记或IVD标记物组，其中IVD标记对肿瘤疾病具有高度敏感性，（ii）确定 由于IVD标记/ IVD标记物组的适应参考范围，患者的比例为阳性，其中参考范围被改编为使得具有假阴性测试的个体数量，具有假阳性测试的个体数量和个体数量 最终需要进行成像诊断以澄清假阴性和假阳性结果在彼此之间相互平衡，使得可以进行肿瘤筛选，可能：（iii）决定执行特定于各自肿瘤疾病的成像方法 用于澄清可能的假阴性和/或假阳性IVD结果，或（iv）在限定的时间间隔后重复阶段（i）和（ii），或（v）进行成像 肿瘤成像方法。